
EquitySector - HealthcareVery High Risk
Direct
NAV (16-Jan-26)
Returns (Since Inception)
Fund Size
₹327 Cr
Expense Ratio
0.72%
ISIN
INF0QA701AB9
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
27 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-0.11%
+1.13% (Cat Avg.)
Since Inception
-3.40%
— (Cat Avg.)
| Equity | ₹318.88 Cr | 97.59% |
| Debt | ₹0.46 Cr | 0.14% |
| Others | ₹7.41 Cr | 2.27% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Divi's Laboratories Ltd | Equity | ₹28.91 Cr | 8.85% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹26.18 Cr | 8.01% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹19.26 Cr | 5.90% |
| Aurobindo Pharma Ltd | Equity | ₹18.08 Cr | 5.53% |
| Cipla Ltd | Equity | ₹16.91 Cr | 5.18% |
| Piramal Pharma Ltd | Equity | ₹13.7 Cr | 4.19% |
| Neuland Laboratories Ltd | Equity | ₹12.65 Cr | 3.87% |
| Emcure Pharmaceuticals Ltd | Equity | ₹11.19 Cr | 3.42% |
| Fortis Healthcare Ltd | Equity | ₹10.62 Cr | 3.25% |
| Rubicon Research Ltd | Equity | ₹10.17 Cr | 3.11% |
| Future on Max Healthcare Institute Ltd Ordinary Shares | Equity - Future | ₹9.65 Cr | 2.95% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹8.92 Cr | 2.73% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹8.69 Cr | 2.66% |
| Lupin Ltd | Equity | ₹7.65 Cr | 2.34% |
| Biocon Ltd | Equity | ₹7.47 Cr | 2.29% |
| Ipca Laboratories Ltd | Equity | ₹7.16 Cr | 2.19% |
| Pfizer Ltd | Equity | ₹6.64 Cr | 2.03% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹6.55 Cr | 2.00% |
| Eternal Ltd | Equity | ₹6.51 Cr | 1.99% |
| Zydus Wellness Ltd | Equity | ₹6.27 Cr | 1.92% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹6.27 Cr | 1.92% |
| Godrej Consumer Products Ltd | Equity | ₹6.11 Cr | 1.87% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹5.89 Cr | 1.80% |
| Net Receivables / (Payables) | Cash | ₹-5.88 Cr | 1.80% |
| Shaily Engineering Plastics Ltd | Equity | ₹5.61 Cr | 1.72% |
| Dr. Lal PathLabs Ltd | Equity | ₹5.22 Cr | 1.60% |
| Bajaj Finserv Money Market Dir Gr | Mutual Fund - Open End | ₹5.06 Cr | 1.55% |
| Abbott India Ltd | Equity | ₹5.04 Cr | 1.54% |
| Medi Assist Healthcare Services Ltd | Equity | ₹4.62 Cr | 1.41% |
| Medplus Health Services Ltd | Equity | ₹4.17 Cr | 1.28% |
| Torrent Pharmaceuticals Ltd | Equity | ₹3.98 Cr | 1.22% |
| Rainbow Childrens Medicare Ltd | Equity | ₹3.89 Cr | 1.19% |
| Jubilant Pharmova Ltd | Equity | ₹3.76 Cr | 1.15% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹3.66 Cr | 1.12% |
| Hindustan Unilever Ltd | Equity | ₹3.61 Cr | 1.10% |
| Syngene International Ltd | Equity | ₹3.59 Cr | 1.10% |
| Tata Consumer Products Ltd | Equity | ₹3.58 Cr | 1.09% |
| Emami Ltd | Equity | ₹3.42 Cr | 1.05% |
| Alembic Pharmaceuticals Ltd | Equity | ₹3.38 Cr | 1.03% |
| Mankind Pharma Ltd | Equity | ₹3.19 Cr | 0.98% |
| AstraZeneca Pharma India Ltd | Equity | ₹2.95 Cr | 0.90% |
| Marico Ltd | Equity | ₹2.37 Cr | 0.73% |
| Kwality Walls (India) Limited ** | Equity | ₹0.06 Cr | 0.02% |
Large Cap Stocks
39.28%
Mid Cap Stocks
23.38%
Small Cap Stocks
34.91%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹271.68 Cr | 83.15% |
| Consumer Defensive | ₹25.36 Cr | 7.76% |
| Consumer Cyclical | ₹6.51 Cr | 1.99% |
| Basic Materials | ₹5.61 Cr | 1.72% |
Standard Deviation
This fund
--
Cat. avg.
15.84%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better

Since December 2024

Since December 2024

Since December 2024
ISIN INF0QA701AB9 | Expense Ratio 0.72% | Exit Load 1.00% | Fund Size ₹327 Cr | Age 1 year | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹32,366 Cr
Address
8th floor, E-Core,Solitaire Business Hub (formerly Marvel Edge), Viman Nagar 411014
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments